Search
forLearn
5 / 801 resultslearn ACETYL TETRAPEPTIDE-2
learn Folate
learn octapeptide-2
learn HT-B
Research
5 / 1000+ results
research Incidence of adverse cutaneous drug reactions in a Mexican sample: an exploratory study on their association to tumour necrosis factor alpha TNF2 allele
Mexican patients had a lower incidence of skin reactions to drugs and no significant link between these reactions and the TNF2 gene variant.
research Macrophages Regulate Schwann Cell Maturation after Nerve Injury
Macrophages help heal nerves by aiding the maturation of Schwann cells and are important for nerve repair.
research The role of hair follicles and Edar signalling in cutaneous wound healing
Activating the Eda/Edar pathway improves wound healing by enhancing hair follicle growth.
research Immune-Mediated Skin Reactions Induced by Recombinant Antibodies and Other TNF-Alpha Inhibitors
TNF-alpha inhibitors can cause various immune-related skin issues.
research Novel RNF113A Variant Underlying X‐Linked Trichothiodystrophy With Presumed Mosaicism in an Unaffected Mother
A new genetic variant causes trichothiodystrophy in two brothers, but their mother may carry it without showing symptoms.
Community Join
5 / 1000+ resultscommunity Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community TGF-Beta. Good or Bad? Help for treatment investment
TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.
community What is preventing GT20029 from being the cure to androgenetic hair loss?
GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community GT20029 phase II results release date?
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.